Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. [electronic resource]
Producer: 20110106Description: 683-95 p. digitalISSN:- 1878-3686
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Humans
- MAP Kinase Signaling System
- Melanoma -- drug therapy
- Mitogen-Activated Protein Kinase Kinases -- antagonists & inhibitors
- Phosphatidylinositol 3-Kinases -- physiology
- Phosphoinositide-3 Kinase Inhibitors
- Phosphorylation
- Proto-Oncogene Proteins B-raf -- antagonists & inhibitors
- Proto-Oncogene Proteins c-akt -- metabolism
- Receptor, IGF Type 1 -- antagonists & inhibitors
- raf Kinases -- physiology
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.